Q32 Bio Inc. (QTTB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Q32 Bio Inc. (QTTB) closed at USD 8.01 on 2026-10-14, a change of +212.9 % over the past year, with a market capitalization of USD 231.31M.

Q32 Bio Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Q32 Bio Inc. key figures

Previous close

USD 8.01 (2026-10-14)

1-year change

+212.9 %

Market cap

USD 231.31M

Enterprise value

USD 130.33M

P/E ratio (trailing)

2.58

P/E ratio (forward)

-7.62

EPS (trailing)

3.01

EPS (forward)

-1.02

PEG ratio

n/a

Price to book

1.74

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.14

Employees

22

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Q32 Bio Inc.

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Q32 Bio Inc. and compare it with other stocks.